Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

R. Buhl, M. Solèr, J. Matz, R. Townley, J. O'Brien, O. Noga, K. Champain, H. Fox, J. Thirlwell, G. Della Cioppa

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

The ability o f omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 μg·day-1) than in the placebo group (43 μg·day-1). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups. In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalEuropean Respiratory Journal
Volume20
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Asthma
Beclomethasone
Placebos
Omalizumab
Adrenal Cortex Hormones
Therapeutics
Steroids
Research Personnel
Incidence

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., ... Della Cioppa, G. (2002). Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal, 20(1), 73-78. https://doi.org/10.1183/09031936.02.00278102

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. / Buhl, R.; Solèr, M.; Matz, J.; Townley, R.; O'Brien, J.; Noga, O.; Champain, K.; Fox, H.; Thirlwell, J.; Della Cioppa, G.

In: European Respiratory Journal, Vol. 20, No. 1, 2002, p. 73-78.

Research output: Contribution to journalArticle

Buhl, R, Solèr, M, Matz, J, Townley, R, O'Brien, J, Noga, O, Champain, K, Fox, H, Thirlwell, J & Della Cioppa, G 2002, 'Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma', European Respiratory Journal, vol. 20, no. 1, pp. 73-78. https://doi.org/10.1183/09031936.02.00278102
Buhl, R. ; Solèr, M. ; Matz, J. ; Townley, R. ; O'Brien, J. ; Noga, O. ; Champain, K. ; Fox, H. ; Thirlwell, J. ; Della Cioppa, G. / Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. In: European Respiratory Journal. 2002 ; Vol. 20, No. 1. pp. 73-78.
@article{df1011205a3a47349e7abe8d96c7499b,
title = "Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma",
abstract = "The ability o f omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5{\%}) than placebo-treated patients (13.5{\%}) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 μg·day-1) than in the placebo group (43 μg·day-1). Disease control was sustained in 76{\%} of omalizumab patients compared with 59.4{\%} of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups. In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma.",
author = "R. Buhl and M. Sol{\`e}r and J. Matz and R. Townley and J. O'Brien and O. Noga and K. Champain and H. Fox and J. Thirlwell and {Della Cioppa}, G.",
year = "2002",
doi = "10.1183/09031936.02.00278102",
language = "English",
volume = "20",
pages = "73--78",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

AU - Buhl, R.

AU - Solèr, M.

AU - Matz, J.

AU - Townley, R.

AU - O'Brien, J.

AU - Noga, O.

AU - Champain, K.

AU - Fox, H.

AU - Thirlwell, J.

AU - Della Cioppa, G.

PY - 2002

Y1 - 2002

N2 - The ability o f omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 μg·day-1) than in the placebo group (43 μg·day-1). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups. In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma.

AB - The ability o f omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 μg·day-1) than in the placebo group (43 μg·day-1). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups. In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma.

UR - http://www.scopus.com/inward/record.url?scp=0035989332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035989332&partnerID=8YFLogxK

U2 - 10.1183/09031936.02.00278102

DO - 10.1183/09031936.02.00278102

M3 - Article

VL - 20

SP - 73

EP - 78

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -